The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Nerve pain refers to painful sensations around the nerves. Various treatment options are available, including anticonvulsants, certain antidepressants, mild opioids, and some topical treatments.

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...